Enliven Therapeutics (ELVN) Non-Current Deffered Revenue (2019 - 2026)
Enliven Therapeutics' (ELVN) quarterly Non-Current Deffered Revenue came in at $217000.0 in Q1 2026, little changed quarter-over-quarter from $217000.0 in Q4 2025.
Enliven Therapeutics (ELVN) Non-Current Deffered Revenue (2019 - 2026) Analysis & Trends
Enliven Therapeutics has disclosed Non-Current Deffered Revenue across 7 years of filings, most recently posting $217000.0 for Q1 2026.
- Non-Current Deffered Revenue for Q1 2026 came in at $217000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $217000.0 (changed N/A YoY), and the FY2025 annual result was $217000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at $217000.0 for Q1 2026 at Enliven Therapeutics, roughly flat from $217000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $4.0 million in Q4 2022 to a low of $217000.0 in Q3 2025.
- The 5-year median for Non-Current Deffered Revenue is $563000.0 (2023), against an average of $796500.0.
- Across the five-year window, Non-Current Deffered Revenue sank 85.84% in 2023 and gained 7.44% in 2024, its largest moves.
- Enliven Therapeutics' Non-Current Deffered Revenue stood at $4.0 million in 2022, then slumped by 85.84% to $563000.0 in 2023, then changed by 0.0% to $563000.0 in 2024, then plunged by 61.46% to $217000.0 in 2025, then changed by 0.0% to $217000.0 in 2026.
- The last three Non-Current Deffered Revenue figures came in at $217000.0 (Q1 2026), $217000.0 (Q4 2025), and $217000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Enliven Therapeutics | 2.32 Bn | 2.32 Bn | - | 217,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 217,000.00 |
| Dec 31, 2025 | 217,000.00 |
| Sep 30, 2025 | 217,000.00 |
| Sep 30, 2024 | 563,000.00 |
| Jun 30, 2024 | 563,000.00 |
| Mar 31, 2024 | 563,000.00 |
| Dec 31, 2023 | 563,000.00 |
| Sep 30, 2023 | 563,000.00 |
| Jun 30, 2023 | 524,000.00 |
| Dec 31, 2022 | 3.98 Mn |
| Dec 31, 2020 | 160,000.00 |
| Sep 30, 2020 | 167,000.00 |
| Jun 30, 2020 | 173,000.00 |
| Mar 31, 2020 | 179,000.00 |
| Dec 31, 2019 | 184,000.00 |